In a campaign to screen drugs for the COVID-19, the disease caused by SARS-CoV-2, treatment, StoneWise, a company specialized in applying artificial intelligence to innovative drug design solutions for innovative drug R&D enterprises and institutions, has conducted research and been sharing the electronic structure data of more than 1400 nucleoside inhibitors against various RNA polymerases from patents up to February 5, 2020. Using its proprietary AI-driven drug design platform, StoneWise has ranked dozens of nucleosides from these molecules as potential inhibitors against SARS-CoV-2 RNA polymerase.
StoneWise hereby makes all the related data freely available to the scientific community for further research and development. The download links are enclosed at the end of this article.
(1) Structured data of RNA polymerase nucleoside inhibitors
(2) Virtual screening of 2019-nCoV RNA polymerase nucleoside compounds and homologous modeling used in this study
